logo 600X600.png
Hemoglobinopathy Market to Surpass US$ 950.6 Million by 2030, Says Coherent Market Insights (CMI)
17 mai 2023 09h01 HE | CMI
Burlingame, May 17, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, Global Hemoglobinopathy Market is estimated to be valued at US$ 636.9 million in 2023 and is expected to exhibit a...
Imara-Logo-Color-RGB.jpg
Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemia
16 nov. 2021 07h00 HE | Imara, Inc.
Positive trend observed in transfusion-dependent subjects treated with higher dose tovinontrine for reduced transfusion burden Tovinontrine was generally well-tolerated in this patient population ...
Imara-Logo-Color-RGB.jpg
Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
11 juin 2021 03h00 HE | Imara, Inc.
Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687 Interim open-label extension clinical trial...
Imara-Logo-Color-RGB.jpg
Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
04 juin 2021 07h00 HE | Imara, Inc.
Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial Imara to host conference call and live webcast on June 11, 2021 at...
Imara-Logo-Color-RGB.jpg
Imara Reports First Quarter 2021 Financial Results and Business Highlights
11 mai 2021 07h00 HE | Imara, Inc.
On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021 Completed enrollment in the...